NeuroDerm, A Mitsubishi Tanabe Pharma Group Company’s Post

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation #stockmarket #stocks #investing #businessnews #trading #daytrading #clinicaltrial

📢 Key Findings from Recent Research on TNF Inhibitors and CNS Disease Risk A new systematic review and meta-analysis published in JAMA Neurology reveals an important consideration for the use of TNF inhibitors in autoimmune diseases: 🔹 36% Increased Risk of CNS Inflammatory Diseases: TNF inhibitors, commonly used to treat autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease, are associated with a higher risk of developing inflammatory central nervous system (CNS) diseases, particularly demyelinating disorders such as multiple sclerosis. 🔹 Risk is Consistent Across Diseases and Inhibitors: The increased risk does not vary significantly between different autoimmune diseases or types of TNF inhibitors. 🔹 Clinical Implication: While TNF inhibitors are highly effective for managing autoimmune diseases, clinicians should be aware of this elevated risk and monitor for signs of CNS complications in patients on these therapies. Read more about the full study and its findings to stay updated on this evolving area of research! #Neuroinflammation #AutoimmuneDiseases #Neurology #TNFInhibitors #CNS #MultipleSclerosis #ClinicalResearch #Rheumatology

AstraZeneca Case Series Shows Long-Term Efficacy and Convenience of Ravulizumab in Generalized Myasthenia Gravis #neurology NeurologyLive https://lnkd.in/gWdHebPN

“Cognivue Clarity® in the Detection of Biomarker-Confirmed Mild Cognitive Impairment and Alzheimer’s Disease” was a poster presented at the American Academy of Neurology (AAN) Annual Meeting in April. The data has been published in Neurology, Volume 102, Number 17 Supplement 1, April 09, 2024. Key Findings: Cognivue Clarity® discriminated healthy controls from those with Mild Cognitive Impairment (MCI) and Alzheimer’s disease (AD), strongly correlated with AD biomarkers, and had strong psychometric properties. The Bio-Hermes study, funded by the Global Alzheimer's Platform Foundation, enrolled healthy controls, as well as patients with MCI and AD. Assessments included sociodemographics, Cognivue Clarity, plasma AD biomarkers, and amyloid positron emission tomography (PET) scans. Cognivue Clarity’s psychometric properties, diagnosis discrimination, correlations with AD biomarkers, and diagnostic power were analyzed. Journal Publication: https://bit.ly/3Jw6l2s Link to see the poster: https://bit.ly/3JsUORg #alzheimersdisease #alzheimers #ad #mildcognitiveimpairement #cognitivehealth #earlydetection #cognitivetesting #dca #biomarkers #biohermes #AANAM Cognivue, Inc.

It's incredibly gratifying to witness the realization of an idea I've been advocating for publicly over the years. The concept was to counteract the resistance to levodopa, a cost-effective treatment for the initial symptoms of Parkinson's disease, by introducing a skin patch or subcutaneous injection. This approach aimed to circumvent the inactivation of levodopa by gut microbes, presenting a strategic solution to a longstanding issue. The recent success of Neuroderm's positive phase 3 results, aligning with this very principle, marks a significant milestone in the field. #parkinson #neuroscience #neurology #neuroderm #Mitsubishitanabe

The first results from the platform trial MND-SMART, led by UK DRI Director Prof Siddharthan Chandran, Prof Suvankar Pal, and the Euan MacDonald Centre for Motor Neuron Disease Research at the University of Edinburgh, have been reported in the Lancet Neurology. The trial aims to significantly speed up delivery of new treatments for motor neuron disease (MND). Memantine and trazodone were tested & found not to be effective compared with placebo - but the innovative trial design has halved the time taken to test these treatments. Prof Siddharthan Chandran said: “There is an urgent need for new treatments for people affected by MND. Through MND-SMART, we have halved the time taken to conclusively test two drugs, showing the trial is doing exactly what it set out to. Momentum is gathering, and I am hopeful that this approach will, in time, deliver effective, disease-modifying treatments for people with MND.” Read the full story ⬇️

At the 2024 American Academy of Neurology conference, significant findings were unveiled regarding the efficacy and safety of Ocrelizumab in the treatment of multiple sclerosis (MS). Insights from the Phase IIIb ENSEMBLE Trial and the Matched Real-world NTD MS Registry Cohort revealed sustained low disease activity over four years of Ocrelizumab therapy in treatment-naive patients with high-activity, early-stage relapsing-remitting MS. Moreover, the ENSEMBLE Study showcased promising outcomes of 10 years of Ocrelizumab treatment, demonstrating its enduring efficacy and safety. Additionally, results from the OCARINA II Phase III Study highlighted the effectiveness of subcutaneous administration of Ocrelizumab in Multiple Sclerosis patients. Read more about RRMS treatment options @ https://lnkd.in/gu5sF5Ve #AAN2024 #Ocrelizumab #MultipleSclerosis #NeurologyConference #ENSEMBLEtrial #OCARINAII #MSresearch

Excited to share our new paper in Frontiers in Neurology which was published today. The paper, titled “Spectris™ Treatment Preserves Corpus Callosum Structure in Alzheimer’s Disease,” highlights the potential of Cognito’s Spectris™ as a disease-modifying candidate for #Alzheimer’s disease (AD). 🧠🧠 This is the first study to report on the ability of Spectris to preserve the corpus callosum in patients with mild to moderate Alzheimer’s disease. The corpus callosum is responsible for information transfer between the brain's hemispheres and plays a crucial role in maintaining #cognitive function. “The results highlight that preserving the structural integrity of the brain’s communication pathways could potentially slow cognitive decline and improve daily functioning,” said Ralph Kern, M.D., MHSc, Chief Medical Officer at Cognito Therapeutics. “This study supports Spectris as a potential disease-modifying therapy in Alzheimer’s, providing a different treatment modality beyond traditional drug-based approaches. Read the full release: https://lnkd.in/eEEhHdPy

Global Neurology Clinical Trials Market size is projected to be valued at USD 5,549.3 million in 2024 and is further expected to grow significantly during the forecast period (2024-2032) at a CAGR of 5.8% and reach USD 9,231.2 million by 2033. #neurologytrials #clinicalresearch #neuroinnovation #brainhealth #neurologicaldisorders #clinicaltrials #neuroscienceresearch #pharmatrials #healthcareadvancement #neurotherapies #marketsize #marketshare #marketanalysis #marketgrowth #markettrend #marketresearch https://lnkd.in/drmR4Kdi

Fierce Pharma recently revisited Spherix's research regarding neurologists' perceptions of Leqembi for Alzheimer's Disease (AD), echoing a previous article from February discussing Leqembi's launch.   One of the key Spherix findings Fierce Pharma called out was how few surveyed neurologists have been recommending Leqembi to patients.   Read the full article here: https://lnkd.in/etnCdctf   #AlzheimersDisease #Neurology #FiercePharma #Leqembi